Welcome to our dedicated page for Senzime Ab news (Ticker: snzzf), a resource for investors and traders seeking the latest updates and insights on Senzime Ab stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Senzime Ab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Senzime Ab's position in the market.
Senzime (OTCQX:SNZZF) announced that its TetraGraph System was added to agreements with Vizient, Premier, and HealthTrust Performance Group on April 24, 2026. These three GPOs serve roughly 95% of US hospitals and have combined annual purchasing volumes exceeding USD 200 billion. The company said GPO listings remove procurement barriers, may shorten sales cycles with pre-negotiated pricing, and could help convert pipeline opportunities into orders, supporting broader US commercial expansion over time.
Senzime (OTCQX:SNZZF / STO:SEZI) published its 2025 annual and sustainability report on April 24, 2026, available on the company website.
The company reports it exceeded SEK 100 million in sales, increased growth rate, met its sales growth targets in constant currencies, kept costs according to plan, secured several strategic wins, and says it laid the foundation for profitability in 2026.
Senzime (OTCQX:SNZZF) reported Q1 2026 results: net sales SEK 23,233k (‑1%; currency‑adjusted +11%), gross margin 63.1%, operating expenses SEK 35,562k and operating loss before depreciation SEK -20,202k. Profit after financial items was SEK -23,242k and EPS -0.14 SEK.
Cash and cash equivalents were SEK 55,353k with an unused credit facility of SEK 42,500k. Cash flow improved by 33% (SEK 12.7m). Management says US timing shifts temporarily slowed growth but full‑year 2026 targets and profitability guidance remain on track.
Senzime (OTCQX:SNZZF) announced on April 20, 2026 an expanded contract with a leading southeastern US hospital system for an additional 65 TetraGraph systems.
The network will now have over 160 TetraGraph installations, generating an estimated annual recurring revenue > SEK 6 million. Senzime has delivered more than 5,000 TetraGraphs and its solutions are used in over 750 hospitals.
Senzime (OTCQX:SNZZF) calls its Annual General Meeting for 19 May 2026 at 16:00 in Uppsala.
Key items include re-election of board members, no dividend for 2025, proposed board remuneration framework (cash up to SEK 2,025,000 plus share rights), introduction of Class C shares with reduced voting rights, a Board Program 2026, proposals for directed issues and repurchase authorizations, and reappointment of Öhrlings PwC as auditor. Total shares outstanding: 157,215,046.
Senzime (OTCQX:SNZZF) invites investors, analysts and media to presentations of its Q1 2026 report on April 22, 2026. The report will be published at 08:00 CEST, followed by a CEO webcast at 09:00 CEST on Senzime's investor site and a live Q&A at 11:00 CEST hosted by Redeye.
Questions for the Q&A must be emailed by April 22, 10:00 CEST to gustaf.meyer@redeye.se. A recording of the Q&A will be posted later the same day on Redeye's website.
Senzime (OTCQX:SNZZF) announced secured contracts to supply TetraGraph systems to hospitals within a major US integrated delivery network, representing a potential scope of more than 150 hospitals. Initial deliveries to a first group of hospitals have begun, positioning this as potentially the company's largest US system-wide agreement to date.
The TetraGraph monitor is presented as supporting compliance with recent ASA and ESAIC guidelines and aims to optimize neuromuscular blockade dosing, reduce complications, and lower anesthesia drug costs.
Senzime (OTCQX:SNZZF) launched TetraCom on February 19, 2026, a hospital connectivity platform that transmits real-time neuromuscular data from the TetraGraph monitor into major EHRs like Epic and Oracle Health (Cerner).
TetraCom combines a compact hardware gateway and cloud software using HL7 messaging to enable wireless, monitor-independent data interoperability and automated, guideline-compliant documentation; initial availability is in the US market.
Senzime (OTCQX:SNZZF) announced on February 18, 2026 a 50 MSEK credit line facility provided by existing shareholders including Crafoord, Segulah and DBT Capital (part of Noba Bank Group).
The facility combines a term loan and a revolving credit portion for working capital peaks, carries market terms, and contains no warrants or dilutive conversion rights. Management says the funding confirms shareholder commitment and supports rapid growth and working capital flexibility.
Senzime (OTCQX:SNZZF) reported strong 2025 growth with net sales +78% to MSEK 104.0 and currency-adjusted sales of MSEK 111.2. Q4 net sales rose 102% to MSEK 28.3 (currency-adjusted MSEK 31.5).
Gross margin before depreciation fell to 52.6% for 2025 (adjusted 62.9% after a MSEK 10.7 inventory write-down). Operating profit before depreciation improved to MSEK -88.4 (adjusted). Cash was MSEK 74.0 at year-end. Company aims for profitability and positive cash flow in 2026.